About Sai Parenteral's IPO
Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing.
The company operates in two segments: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) products and services for domestic and international markets.
The product portfolio spans multiple therapeutic areas including cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology. Offerings are across dosage forms such as injectables, tablets, capsules, liquid orals, and ointments.
Sai Parenteral's serves a wide customer base comprising central and state government agencies, pharmaceutical companies, public and private hospitals, and super stockists in India. The company entered exports in FY 2023 after acquiring two internationally accredited facilities in Hyderabad, Telangana, and now supplies to regulated and semi-regulated markets in Australia, New Zealand, Southeast Asia, the Middle East, and Africa.
The company owns and operates five manufacturing facilities in India. Four are located in Hyderabad, Telangana, comprising a GMP-compliant injectable unit, a WHO-GMP injectable unit, a TGA-Australia and PIC/S accredited solid oral dosage unit, and a WHO-GMP cephalosporin facility. Its wholly owned subsidiary, Revat Laboratories, operates a GMP-certified facility in Ongole, Andhra Pradesh.
As of December 31, 2025, Sai Parenteral Ltd. employed 298 full-time employees.
Sai Parenteral's IPO Subscription Breakdown
| Investory Category | Subscription Percentage | Amount Raised (₹ Crores) |
|---|---|---|
| Qualified Institutional Buyers (QIBs) | 50% | 37,61,243 crores |
| Non-Institutional Investors (NIIs) | 15% | 11,28,372.9 crores |
| Retail Individual Investors (RIIs) | 35% | 26,32,870.1 crores |
Sai Parenteral's IPO Financial Highlights
Sai Parenteral's’s total income 0.00 by 0.00% and total expenses 0.00 by 0.00%, resulting in an EBITDA 17.64 by -44.35% and a profit after tax (PAT) 0.00 by 0.00% between March 31, 2025 and March 31, 2026.
17.6431 March 2026 | 31.731 March 2025 | 39.4431 March 2024 |
39.44
35
32
28
24
20
16
12
8
4
0.00
Sai Parenteral's IPO Strengths & Weaknesses
Diversified generic formulations player with an established track record.
Strategically located and accredited Manufacturing Facilities.
Strong focus on CDMO business.
Well-established distribution network in India and overseas.
Track record of value-accretive acquisitions.
Experienced Promoters and Senior Management with extensive domain knowledge.
Sai Parenteral's IPO Important Dates & Issue Details
| Allotment Date | Listing Date | Refund Date |
|---|---|---|
| 30 Mar '26 | -- | 01 Apr '26 |
| Issue Composition: | |
|---|---|
| Face Value | ₹5 per share |
| Total Issue Size | 75,22,486 shares (aggregating up to ₹14,896 crores) |
| Fresh Issue | 14,54,081.6 shares (aggregating up to ₹72,70,408 crores) |
| Offer for Sale | 6,31,576 shares of ₹5 (aggregating up to ₹31,57,880 crores) |
| Issue Type | Book building |
| Post-Issue Shareholding Pattern: | |
|---|---|
| Pre-Issue Shareholding | 61.23 shares |
| Post-Issue Shareholding | 51.2 shares |
Sai Parenteral's IPO Lot Size and Investment Details
| Minimum Lot Size | -- |
| Maximum Lot Size (Retail) | -- |
The lot size of Sai Parenteral's ipo has been designed to ensure broad participation while maintaining optimal price discovery.
How to Apply for Sai Parenteral's IPO
- Log in to your Choice account
- Select IPO
- Enter the number of lots and your price
- Verify UPI ID
- Complete the transaction on your UPI app
Sai Parenteral's IPO Contact & Registrar Details
Contact Details
Address
Plot No39 5th Floor Lavanya Arcade Jayabheri Enclave Gachibowli K V Rangareddy
Phone Number
Website
Registrar Details
Registrar Name
Bigshare Services PvtLtd
Phone Number
Optivalue Tek Consulting Ltd IPO Lead Manager(s)
| Book Running Lead Manager(s) |
|---|
| Arihant Capital Markets Ltd |